Podcast by STAT
Episode 183: Greg Zuckerman on the vaccine race, plus Biogen's troubled launch
Wall Street Journal reporter Gregory Zuckerman joins us to share some behind-the-scenes details from race to develop a Covid-19 vaccine, the subject of his new book. We also discuss the latest news in the life sciences, including Biogen’s failure to launch, the plight of a Covid pill, and a headline-grabbing statement from one of biotech’s most famous scientists.
Episode 182: The FDA star search, more booster debates, & the future of mRNA
STAT Washington correspondent Nicholas Florko joins us to provide an inside look at the eleventh-hour search for a permanent FDA commissioner. We also discuss the latest twist in the debate over Covid-19 vaccine boosters, some upheaval in the world of genome editing, and a little news for parents from one Scott Gottlieb.
Episode 181: Brent Hodge on filming Shkreli, the next NIH director, and a looming FDA deadline
First, we discuss the scramble to find new leaders for the NIH and FDA, the latest online dustup involving Ginkgo Bioworks, and the growing promise of antiviral treatments for Covid-19. Then, filmmaker Brent Hodge joins us to discuss his documentary "Pharma Bro," which chronicles the trial, conviction, and prolific livestreaming of one Martin Shkreli.
Episode 180: Health equity 'tourism,' an $11B biopharma acquisition, & a bony Covid protest
First, we welcome STAT reporter Usha Lee McFarling onto the podcast to discuss her investigation into health equity tourism — how white scholars are colonizing research on health disparities. Then, we "chatty Cathy" a blizzard of biotech news from this week, including Merck's $11 billion acquisition of Acceleron Pharma, a theatrical street protest about the Covid vaccine equity dive, a debate about gene therapy's future, and, finally, why Scott Gottlieb is looking up at Elvira.
Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout
First, STAT's Helen Branswell joins us to discuss the state of the Covid-19 pandemic as we head into another winter. Then, former FDA Commissioner Scott Gottlieb calls in to discuss his new book on how the U.S. got caught off guard and what the government needs to do before the next pandemic hits. We start with a look at the latest news in the life sciences, including the booster debate, Biogen's trouble selling its controversial Alzheimer's drug, and the awkward pairing of beer and face masks.
Episode 178: Futuristic prosthetics, a treatment for ALS, & intrigue at the Holmes trial
Can prosthetic limbs feel real? Is the FDA softening under pressure? And are Rice Krispies Treats admissible in court?
STAT's Gideon Gil joins us to share the remarkable story of an amputation surgery that makes a phantom limbs feel like the real thing. Then we discuss the FDA's surprising reversal on a new treatment for ALS and whether it signals a sea change within the agency. We start with a look at the latest news in the life sciences, including the debate over Covid-19 vaccine boosters, the future of in-person conferences, and a mysterious sweet-toothed observer at Elizabeth Holmes's fraud trial.
It’s obvious the hosts of this podcast are working reporters, and good ones at that. The show topics are exactly what I want to know about biotech each week. I’m also a big fan of the “chatty Cathy” segment.
Highly quality podcast
Best biotech podcast ever
Love love this podcast! Wanted to to find something similar for a long time! I am glad I was able to find this podcast. The hosts are so knowledgeable and articulate.
Good flow, interesting story, and wonderful people! I just want more! Maybe twice a week?